News

Portfolio Snapshot: Minuum debuts on Google Glass, Crowdmark named most innovative at SIIA

There’s been lots of activity in MI’s portfolio this week (and it’s only Wednesday). Read down for what you need to know about Whirlscape, Crowdmark, OtoSim, and ApneaDx.

Whirlscape logoWhirlscape launches Google Glass demo video

Whirlscape’s Minuum keyboard nabbed a four-star review from CNET’s editors only days before announcing their technology is now available for Google Glass. Watch the UTEST graduate‘s newest demo video.

Reaction coverage: BNN, the Telegraph (U.K.), WPRO (radio), CNET, Mashable, TechCrunch, Mobile Syrup and Android Central, among various other tech blogs.

Crowdmark Logo: Grade BetterCrowdmark named “Most Innovative” at SIIA conference

The Education Division of the Software & Information Industry Association (SIIA) showcased some of the newest and most innovative products in the education technology market, and recognized the best among them as part of the Innovation Incubator program at the 13th annual Education Industry Summit, the leading conference for the K-12 and postsecondary education technology market, held May 12-14 at the Palace Hotel in San Francisco.

From their blog:

Crowdmark was named Most Innovative among more than 50 applicants,

Continue Reading

MI’s Fanny Sie to speak about 3D printing trends at two Toronto events

Fanny-Sie-web-7227
Fanny Sie is a manager in MI’s Technology & Venture Development group and head, Imaging Technologies Area.

Fanny Sie, MaRS Innovation’s head of imaging technologies and a manager in the Technology & Venture Development group, is speaking about bioprinting trends at two Toronto conferences this weekend.

Sie is MI’s commercialization lead on the Bioprinter, a licensenable technology from the University of Toronto and Sunnybrook Health Sciences Centre.

Watch her interview on bioprinting with TVO’s The Agenda, which aired in June 2013.

First up is Digifest, an international festival celebrating digital creativity, which runs from May 8 to 10 at the Corus Quay building on Toronto’s Waterfront. Sie will speak about 3D printing and its biological and commercial implications on the Mass Customization Panel Discussion, which runs from 2 to 3 pm on Friday, May 9.

On Monday, Sie joins the opening panel at the OCE Discovery Conference, which runs from May 12 to 13, 2014 at the Metro Toronto Convention Centre (South Building). She will speak during the “3D Manufacturing: Beyond the Hype” panel at 9 am on May 13.

Continue Reading

MaRS Innovation Statement on 2014 Ontario Budget

TORONTO, ON (May 2, 2014) – MaRS Innovation congratulates the government’s deepened commitment to support the life sciences through research and innovation funding. In particular, the new $30 million Life Sciences Seed Venture Capital Fund will create a partnership between the Province of Ontario, the private sector and hospital foundations to finance Ontario-based life sciences companies.

Dr. Raphael Hofstein
Dr. Raphael Hofstein, president & CEO, MaRS Innovation.

“As co-designers of this venture capital fund and one of its many champions, MaRS Innovation welcomes this news,” says Dr. Raphael (Rafi) Hofstein, president and CEO. “We look forward to the strong collaborations it will foster with our colleagues in the Government of Ontario, private industry and the hospital community.”

“By their nature and the need for regulation, life sciences companies take considerable time to mature products and their underlying technologies. Expanding the funding available during this critical stage through this unique public-private partnership will give more Ontario start-ups emerging with disruptive technologies from the province’s academic institutions the financing they need to succeed and thrive,” says Hofstein.

Continue Reading

WaveCheck breast cancer technology receives $100,000

OICR’s catalyst grant enables WaveCheck to open first partner site at MD Anderson Cancer Center in May

WavecheckTORONTO, April 8, 2014 — People with breast cancer are a step closer to knowing if their tumour is responding to chemotherapy at the start of treatment, thanks to a $100,000 catalyst grant from the Ontario Institute for Cancer Research (OICR).

The funding builds upon MaRS Innovation‘s Indiegogo crowdfunding campaign for WaveCheck, which successfully raised over $50,000 from over 500 supporters worldwide in two months last fall.

Read Jane Gerster’s article for the Toronto Star about OICR’s catalyst grant for WaveCheck. This announcement was also covered in Metro, BetaKit and Council of Academic Hospitals of Ontario’s Catalyst newsletter.

WaveCheck, a clinical technique invented, refined and tested by scientists at Sunnybrook Health Sciences Centre and Ryerson University over 20 years, aims to show whether chemotherapy is actually destroying a breast cancer tumour at the beginning of chemotherapy treatment (in as little as four weeks), rather than at the end of treatment (typically four to six months).

In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology (shown here) shows promise as an accurate, efficient way to monitor tumour response. Sunnybrook has partnered with GE Healthcare to co-develop WaveCheck as a clinical tool.
In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology (shown here) shows promise as an accurate, efficient way to monitor tumour response. As of March 2015, Sunnybrook has partnered with GE Healthcare to co-develop WaveCheck as a clinical tool.

In early clinical testing, the non-invasive, image-guided technology has shown promise as an accurate, efficient way to monitor tumour response, opening the door to tailored treatment.

“This is a significant step towards achieving the goal of personalized medicine. The clinical trials will confirm that information provided by WaveCheck can determine if the treatment is the appropriate one or that other options should be chosen, sparing patients the side effects of treatments that will not likely be successful,” said Dr. Tom Hudson, OICR’s president and scientific director. “If successful, WaveCheck could become a standard tool in the cancer treatment of the future.”

Continue Reading

MaRS Innovation Industry Access Program (MI-IAP) accepting applications until April 10

Researchers working in orphan indications, drug delivery devices, big data and other key areas invited to submit a brief Statement of Interest

The commercialization process: Moving transformational ideas from the lab bench to the street
MaRS Innovation’s commercialization process helps inventors move their transformational ideas from the lab bench to the street.

The MaRS Innovation Industry Access Program (MI-IAP) is a simple, formalized process for marketing early-stage technologies to MI’s industry partners: Baxter, LifeLabs (formerly CML Healthcare), GSK, Johnson & Johnson, Pfizer and Merck.

The program’s goal is to secure funding for researchers within MI’s membership through these collaborative, strategic R&D partnership programs.

First run in November 2013, the MI-IAP allows researchers to easily determine whether an industry partner is interested in co-developing their technologies. The application process is deliberately brief at the outset.

Ben Rogers
Ben Rogers, director, technology transfer & scouting

“Last fall, we received 28 statements of interest, 12 of which we invited to submit a non-confidential summary package,” said Ben Rogers, director, Technology Transfer & Scouting. “Of these, six have been invited for a technology presentation with an industry partner. We’d like to see all of those numbers grow during this application round.”

The program will also make it easier for researchers to find prospective industry partners.

Continue Reading

UTEST’s co-directors share what makes for a great start-up application

utestThe University of Toronto Early-Stage Technology (UTEST) program helps U of T students, recent grads or professors to take their ideas to market.

Successful applicants get mentoring, funding and work space over a 12-month period as they advance their ideas. The program is co-managed by MaRS Innovation and the University of Toronto.

In a U of T “Spotlight on Startups” news article, Brianna Goldberg spoke with Mike Betts and Kurtis Scissons, UTEST co-directors, on what makes for a great applicant.

Here’s an excerpt:

What are you looking for in an exceptional UTEST application?
Evidence of a strong and committed team.  It’s critical to have standout technology and a great market opportunity but at the end of the day it’s the team that makes these businesses work—it’s about having a balance of amazing technical talent and business leadership and execution skills. When we come across an application that has a really awesome team, it stands out. – Mike Betts, UTEST co-director

What’s one common mistake you see in applications for UTEST that might cause them to be rejected?
Commitment. We want entrepreneurs that are fully committed to the program and to their new companies. UTEST is a serious program for serious entrepreneurs who want support to create a sustainable successful company. The application must exude your confidence in your idea and the effort the entrepreneur(s) will commit to see it successful. – Kurtis Scissons, UTEST co-director

What advice would you give to those considering applying to UTEST?
1. Build a balanced team. Understand the strengths of your team members and ensure that gaps can be addressed either through internal change or be open to external hires.

2. Be passionate about your idea but also understand it will be a rollercoaster of emotions. –Scissons

Betts and Scissons are accepting applications for UTEST’s third cohort until April 17. Current students, current faculty and recent graduates of U of T are welcome to apply.

Continue Reading

Whirlscape exits beta, launches version 2.0 of the Minuum keyboard

Whirlscape Inc., a graduate of the University of Toronto Early-Stage Technology (UTEST) program’s cohort graduate, exits beta with the version 2.0 release of Minuum, their hit “small keyboard for big fingers.”

Whirlscape Inc. graduated from the University of Toronto Early-Stage Technology (UTEST) program’s first cohort. UTEST is accepting applications for its third cohort until April 17. Click here to apply. 

Version 2.0’s release is already a popular download for Android Apps in the Google Play store. Users can get a 30-day free trial of Minuum and experience new features, including a widely anticipated addition of a Brazilian Portuguese language module, the company’s most requested language.

Screen Shot 2014-03-13 at 10.20.33 AM
Whirlscape Inc. released version 2.0 of the Minuum keyboard with a host of new features, including the highly-requested addition of a Portuguese (BR) language module.

Will Walmsley, Whirlscape’s CEO, spoke with Daniel Bader of MobileSyrup. Here’s an excerpt from the article:

“We’re constantly testing out new features and improving the disambiguation algorithms,” says Will Walmsley, CEO and co-founder of the company he started at U of T’s Dynamic Graphics Project lab. The company raised $500,000 in seed funding earlier this year, and under the advisement of Y Combinator, began releasing often, trialling new features in what they call Bonus Panels, secondary functions that quickly allow users to change languages, add emojis and more.

Continue Reading

Techvibes highlights UTEST’s third cohort

utestTechvibes, a publication dedicated to covering latest trends in start-up culture and social and mobile news, covered the University of Toronto Early-Stage Technology (UTEST) program’s call for applications in an online article on March 1, 2014.

Applications for UTEST’s third cohort are open until April 17, 2014. Co-directors Kurtis Scissons and Mike Betts will work with selected applicants for a period of twelve months to guide their idea to market. Successful applicants receive work space for a year, mentorship, $30,000 in funding and access to industry expertise.

Continue Reading

Quick Links

Contact Us

Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca

© CopyrightTIAP 2024 - All Rights Reserved | Site Map | CASL Policy | Privacy Policy | AODA Compliance
Twitter Linkedin
Back To Top